Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
Clinical trial NCT03834519 · COMPLETED
Trial details
- NCT number
- NCT03834519
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-02
- Primary completion
- 2022-03-14
- Enrollment
- 793
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.